Patents by Inventor Thomas Gramatte

Thomas Gramatte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases
    Patent number: 11261205
    Abstract: The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: March 1, 2022
    Assignee: Morphochem GmbH
    Inventors: Thomas Kapsner, Axel Dalhoff, Thomas Gramatte
  • OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES
    Publication number: 20200392168
    Abstract: The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 17, 2020
    Inventors: Thomas KAPSNER, Axel DALHOFF, Thomas GRAMATTE
  • Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases
    Patent number: 10723746
    Abstract: The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 28, 2020
    Assignee: Morphochem Aktiengesellschaft Für Kombinatorische Chemie
    Inventors: Thomas Kapsner, Axel Dalhoff, Thomas Gramatte
  • OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES
    Publication number: 20160130288
    Abstract: The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.
    Type: Application
    Filed: May 9, 2014
    Publication date: May 12, 2016
    Applicant: MORPHOCHEM AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE
    Inventors: Thomas Kapsner, Axel Dalhoff, Thomas Gramatte
  • Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
    Patent number: 7943176
    Abstract: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: May 17, 2011
    Assignee: Apogepha Arzneimittel GmbH
    Inventors: Thomas Gramatte, Peter Gruber, Michael Heschel, Dirk Pamperin, Jan Ploen, Steffen Scheithauser, Wolfgang Wehner, Peter Guldner
  • Oral Dosage Forms for Propiverine or Pharmaceutically Acceptable Salts Thereof Having Prolonged Release of the Active Agent
    Publication number: 20080317848
    Abstract: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.
    Type: Application
    Filed: April 8, 2004
    Publication date: December 25, 2008
    Applicant: APOGEPHA ARZNEIMITTEL GMBH
    Inventors: Thomas Gramatte, Peter Gruber, Michael Heschel, Dirk Pamperin, Jan Ploen, Steffen Scheithauer, Wolfgang Wehner, Peter Guldner
  • Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
    Publication number: 20040258749
    Abstract: By suitable retardation oral pharmaceutical compositions containing propiverine or one or several pharmaceutically acceptable salts thereof in an amount of 4 mg to 60 mg propiverine and having a prolonged release of the active agent are produced. Preferably a blend of active agent and optionally one or more acidic substances having a pKa value of less than 6.65 are provided with a retarding coating or are embedded in a matrix which is then optionally coated with further retarding layers.
    Type: Application
    Filed: April 8, 2004
    Publication date: December 23, 2004
    Inventors: Peter Guldner, Michael Heschel, Dirk Pamperin, Jan Ploen, Steffen Scheithauser, Wolfgang Wehner, Thomas Gramatte